Summary. Platelet aggregation to collagen in 12 Type 1 (insulin-dependent) diabetic patients with background retinopathy and 12 Type 1 diabetic patients with proliferative retinopathy was compared with an age-and sex-matched control group. An analogue of prostaglandin H2, 11,9 epoxymethano-prostaglandin H2, which directly stimulates thromboxane receptors, and EP 092, which is a competitive thromboxane A2 receptor antagonist, were used to investigate changes at platelet thromboxane receptor level in these groups. The concentration of collagen (ECso) required to give 50% of maximum aggregation did not differ between the two diabetic groups and the control group. However, platelets from the proliferative retinopathy group were significantly more sensitive to the thromboxane mimetic (11,9 epoxymethano-prostaglandin H2) (p<0.005) than the background retinopathy and control groups. This change may be a factor in the development of proliferative retinopathy.
Previous studies in diabetes mellitus have demonstrated abnormalities of platelet function such as exaggerated response to aggregating agents [1] and refractoriness to inhibiting prostaglandins (PG) [2, 3] . Hyperaggregation is reported to be associated with poor glycaemic control [4] , increasing age [5] , and the presence of micro-and macrovascular changes [6, 7] . A number of circulatory substances relevant to coagulation, including lipids [8] , fibrinogen [9] and yon Willebrand factor [10] have also been reported as abnormal in diabetic patients. However, particularly in the presence of vascular complications [11, 12, 13] , the results have been inconsistent, perhaps because of the diverse methods used and the failure to obtain homogenous patient groups.
Where a possible mechanism for enhanced platelet aggregation has been investigated, the most consistent finding has been the increased production of aggregation-induced thromboxane A2 (TXA2) [14, 15] . TXA2, which is the predominant metabolite of platelet arachidonic acid (AA), is a powerful platelet aggregator and vasoconstrictor [16, 17] . Most studies have employed AA itself or an agent such as collagen, which releases endogenous platelet AA, to demonstrate enhanced platelet aggregation. Since the production of TXA2 is known to be increased, it cannot be determined from these studies [11, 12] whether improved receptor coupling or an increase in the number of thromboxane receptors may also contribute to this increased sensitivity.
The aims of this study were to confirm platelet hyperaggregability to collagen and to investigate the changes at receptor level in platelets from diabetic patients with established microangiopathy using an analogue of PGH2, 11,9 epoxymethano PGH2 (11,9-em PGH2), which directly stimulates thromboxane receptors [18, 19] , plus a competitive thromboxane receptor antagonist (EP 092) [20] . Young insulin-dependent diabetic patients who had background and proliferative retinopathy as well as a non-diabetic control group were selected in order to investigate the possible relationship between platelet function and susceptibility to proliferative retinopathy.
Subjects and methods
The patients studied were 24 Type 1 (insulin-dependent) diabetic patients, 12 with background and 12 with proliferative retinopathy. The patients were compared with 12 non-diabetic healthy volunteers. The three groups were comparable for age and sex, and the diabetic groups were matched for duration of diabetes. There was no significant difference between the two diabetic groups in blood glucose, HbA1 or platelet counts at the time of the study. (Table 1 ). Classification of retinopathy was based on ophthalmoscopic and fluorescein angiographic appearances in all patients. In the background retinopathy group three patients had scattered microaneurysms and haemorrhages, seven patients had hard exudative changes and two patients had ischaemic preproliferative changes. None of the diabetic subjects were taking any medication other than insulin, all of the patients were clinically free of nephropathy (urine Albustix negative and plasma creatinine less than 150 ~mol/l) and all had easily palpable peripheral pulses. Blood (100 ml) was collected between 08.00 and 09.00 hours from fasted diabetic patients and control subjects into plastic centrifuge tubes containing acid-citrate dextrose (ACD) anticoagulant and centrifuged at 120 g for 20 rain. The platelet-rich plasma (PRP) was then pre-incubated with [14C] 5-hydroxytryptamine (final concentration 1 ~tg/ml) for 30 min at 37 °C. Platelet aggregation was studied using the photometric method of Born [21, 22] . Dose response curves for aggregation induced by collagen and 11,9-em PGH2 were determined both in the presence and absence of a cyclooxygenase inhibitor, Froben (10 ~tmol/1), which eliminated the production of endogenous TXA2 and allowed assessment of aggregation in the absence of the secondary aggregation wave. In addition, we measured the shift in dose-response curve for aggregation using a fixed concentration of a competitive TXA2 receptor antagonist EP 092 (0.25 ~tmol/1). Each aliquot was warmed to 37 °C for 2 min prior to the addition of the aggregating agents. If used, Froben or EP 092 were added at time zero, 2 min before the addition of the aggregating agent.
Release of platelet dense granule constituents (5HT, ADP) were measured using the radiolabelled isotope [14C] 5-hydroxytryptamine prelabelling technique [22] . Basal platelet cAMP and the rise in cAMP induced by PGEa (0.2 Ixmol/1) were measured by a protein binding assay [22, 23] .
The glycosylated haemoglobin assay was carried out by electrophoresis using commercially available agar plates (Coming Medical, Halstead, UK) as described by Read et al. [24] , the normal range being 6-8%. ll,9-em PGH2 and PGEa were purchased from Upjohn, Kalamazoo, Mi, USA. Collagen was obtained from Diamed Diagnostics Ltd, Liverpool, England. EP 092 was synthesised in the laboratory of the Department of Pharmacology, University of Edinburgh. Flurbiprofen (Froben) was a gift from Boots Pharmaceuticals Ltd, Nottingham, England.
[14C] 5-hydroxytryptamine was purchased from Amersham, UK. All of the solutions were free of ethanol and all subsequent dilutions were made up in 0.9% saline.
Statistical analysis
Statistical analysis of the dose ratios was by Kruskal-Wallis one-way analysis of variance by ranks. Comparison between the groups for the cAMP results was by independent Student's t-test.
Results
There was no difference in the concentration of collagen (ECs0) required to give 50% of the maximum aggregation wave between the two diabetic groups and the control group (Table 2) . Similarly, the thromboxane receptor antagonist EP092 shifted all three curves to a similar extent, as shown by the new ECs0 values in the presence of EP 092, and by the dose ratios (DR) (DR= EC50 in the presence of EP 092/EC50 collagen alone). The cyclooxygenase inhibitor Froben produced a more marked shift of the control aggregation curves than observed with EP 092. Froben appeared to be slightly less effective in the proliferative retinopathy group, but this was not statistically significant.
There was, however, a significant difference between the three groups in the concentration of ll,9-em PGH2 required to induce a 50% aggregation response. Less 11,9-em PGH2 was required for the proliferative retinopathy group than for either the control or retinopathy groups (p < 0.005). Furthermore, EP 092 produced a significantly larger shift in the aggregation curve in the proliferative retinopathy group as judged by the dose Table 3 . Results of platelet release reaction in control and diabetic retinopathy groups due to collagen (2 Ixg/ml) and (250 ng/ml) 11,9 emPGH2 alone and in the presence of EP 092 (0.25 pomol/1) and Froben (10 txmol/l) ratio when compared with the other two groups (p < 0.005). In the presence of Froben no difference was found between the three groups. (Table 2) 5-Hydroxytryptamine release in response to both collagen and 11,9-em PGH2 showed no difference between the three groups (Table 3) .
There was no difference in the basal levels of cAMP found in platelets from the three groups or in the rise in cAMP induced by PGEt (Fig. 1) .
Discussion
This study demonstrated that platelets from Type 1 diabetic patients with proliferative retinopathy are more sensitive to 11,9-em PGH2 than platelets from Type 1 diabetic patients with background retinopathy and control subjects. However, unlike previous studies in diabetic patients [15, [26] [27] [28] , we did not find increased platelet sensitivity to collagen, whether sensitivity was measured as platelet aggregation or as 5-hydroxytryptamine release. In non-diabetic subjects endogenous PGH2 and TXA2 production are the major components of collagen-induced aggregation [29] . The aggregation ECs0 for collagen was similar for the two diabetic and control groups, with the reversible thromboxane antagonist EP 092 producing a similar shift of the aggregation wave in each group. The cyclooxygenase inhibitor Froben appeared to be slightly less effective in the proliferative group than in the background retinopathy and control groups, but this did not achieve statistical significance. The slight decrease in the efficacy of Froben in this group is consistent with increased thromboxane synthesis in response to collagen without alteration in the aggregation ECs0 level. From these observations it would appear that the mechanism for collagen-induced aggregation is similar in both diabetic patients and control subjects.
Age is an important determinant of platelet function in both non-diabetic subjects and diabetic patients [5] . During recruitment to our study we paid particular attention to careful age restriction and comparability. This may account for the apparent discrepancy in platelet collagen sensitivity in diabetic patients in this study compared with other studies [15, [26] [27] [28] .
In contrast, platelets from the diabetic group with proliferative retinopathy were more responsive to the thromboxane mimetic ll,9-em PGH2. This increase in sensitivity was reduced in the presence of the cyclooxygenase inhibitor, Froben. In non-diabetic subjects the major mechanism of the action of the mimetic does not involve activation of the thromboxane generating system [16, 17] . It would appear, therefore, that the increased sensitivity is not a direct effect of the ll,9-em PGH2 on the receptor. The mechanism of increased sensitivity in the proliferative retinopathy group remains undefined; however, it may be due to increased endogenous thromboxane production during secondary aggregation.
There was no difference between either the basal level of platelet cAMP levels or the increased cAMP level after exposure to PGE1 between diabetic patients and control subjects. This is in agreement with a recent study of PGIt binding to platelets [31] and activation of adenylate cyclase, but in sharp contrast to that of Lagarde et al. [32] , where lower resting levels of cAMP and a diminished response to inhibiting prostaglandins were reported. The likely explanation is that in our study and that by Shepherd et al. [31] the subjects were young and age-matched, whereas in the report by Lagarde et al. [32] the ranges of age, duration of diabetes and vascular complications were very wide.
In conclusion, platelets from young Type i diabetic patients with microvascular disease in the form of background and proliferative retinopathy are similar to platelets from normal subjects in their response to collagen-induced aggregation. In contrast, platelets from diabetic patients with proliferative retinopathy demonstrate increased sensitivity to a thromboxane mimetic; this may be a factor in the development of proliferative retinopathy.
